Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Sleep Apnea

The general area is that of preoperative risk management of sleep apnea patients undergoing major surgery. This field is burgeoning with clinical activity. A large amount of healthcare dollars are expended annually in order to detect sleep apnea and offer therapy that is of unproven value. Most all of the data is retrospective case series or a mixture of retrospective and prospective cohort studies. Yet, across the country, ...more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

Physical Activity and Sedentary Behavior Research

There is a need to enhance research efficiency for physical activity and sedentary behavior research by facilitating standardization of the definition of sedentary behavior; employing research strategies that support reliable, valid, and efficient ways to measure and analyze sedentary behaviors; supporting better approaches for data harmonization to promote comparability across studies; and facilitating the use of platforms ...more »

Voting

44 net votes
75 up votes
31 down votes
Active
(@peter0)

Goal 2: Reduce Human Disease

Elucidate the different causes of circadian disorders, and tailor the treatment to the cause

There are several possible physiological causes of Circadian Rhythm Sleep-Wake Disorders (CRSWDs), including lack of sensitivity to light, over-sensitivity to light, deficiencies in the ipRGC cells of the retina, lack of melatonin production, long elimination time of melatonin, long intrinsic circadian period, differences in timing of sleep relative to internal circadian rhythms, differences in tolerance to phase mismatch, ...more »

Voting

47 net votes
58 up votes
11 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Is “renewal” of R01 grants, competitive or not, justifiable?

Does NIH intend to develop a new milestone-based grant system and introduce accountability with regards to reaching solid metrics and useful, quantifiable research goals and milestones? Does NIH intend to introduce a truly non-conflicted and independent grant review system, similar to the review system and accountability of the FDA, to increase research efficiency? Should the public be informed annually how effective ...more »

Voting

-4 net votes
16 up votes
20 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

COPD hospitalizations

COPD hospitalizations a. Define the pathobiological changes that lead to severe exacerbations that cause hospitalizations b. Define novel clinical and biological phenotypic characterizations of hospitalized patients who fail treatment that results in death or early readmission c. Explore new or understudied therapies for treatment of acute COPD hospitalizations: antioxidant, non-steroidal anti-inflammatory (STATIN or ...more »

Voting

3 net votes
3 up votes
0 down votes
Active
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

Enabling technologies that improve the precision and depth by which we evaluate people

How do we enable technologies that improve the precision and depth by which we evaluate patients to better understand pathophysiology and develop, test and optimize therapy?

 

Use of EHR to understand HLB disease?

Should NHLBI/researchers have a larger role in the development of the EHR?

Voting

5 net votes
16 up votes
11 down votes
Active
(@serevill)

Goal 2: Reduce Human Disease

Does lowering circulating lipoprotein(a) levels influence cardiovascular outcomes?

A comprehensive research strategy and plan is needed to determine the most efficient, safe, cost-effective and widely applicable strategy to decrease circulating levels of lipoprotein(a) and to determine whether lowering circulating lipoprotein(a) levels will reduce the risk of developing cardiovascular disease such as a heart attack or a stroke as well as the progression of atherosclerosis or aortic stenosis.

Voting

235 net votes
297 up votes
62 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Rare Diseases

A study section should be seated for clinical trials on rare disease. Members of this study section should consist only of individuals who have previously performed phase I and/or phase II trials, developed IND or IDE applications, or who have extensive experience in informatic or biometric support for clinical trials. My opinion is that seating individuals on these sections who have a laboratory career in cellular or ...more »

Voting

2 net votes
2 up votes
0 down votes
Active